EUCTR2016-000904-27-AT进行中（未招募）1 期
Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus. A 30-week randomised, double-blind, placebo-controlled trial - SUSTAIN 9 – Add-on to SGLT-2i
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Informed consent obtained before any trial-related activities. Trial-related activities are any
- •procedures that are carried out as part of the trial, including activities to determine suitability
- •for the trial.
- •- Male or female, above or equal to 18 years at the time of signing informed consent. For Japan only: Male or female, age = 20 years at the time of signing informed consent.
- •- Diagnosed with type 2 diabetes mellitus
- •- HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive)
- •- Stable dose of an SGLT-2 inhibitor as monotherapy or in combination (including fixed dose drug combination) with a stable dose of metformin (= 1500 mg or maximum tolerated dose) or a SU for at least 90 days prior to the day of screening. All medications in compliance with current local label.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice).
- •- Any disorder which in the investigator’s opinion might jeopardise subject’s safety or compliance with the protocol.
- •- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed.
- •- Subjects with alanine aminotransferase > 2.5 x upper normal limit.
- •- Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative.
- •- History or presence of pancreatitis (acute or chronic).
- •- History of diabetic ketoacidosis.
- •- Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening.
- •- Subjects presently classified as being in New York Heart Association Class IV.
- •- Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
- •- Renal impairment measured as estimated Glomerular Filtration Rate value of eGFR < 60 ml/min/1.73 m^2 as defined by KDIGO 2012 classification using isotope dilution mass spectrometry for serum creatinine measured at screening.
- •- Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within the past 90 days prior to randomisation.
- •- Presence or history of malignant neoplasms within the past 5 years prior to the day of
- •screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetesMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2012-004827-19-BGovo Nordisk A/S1,200
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus.MedDRA version: 19.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2016-000904-27-NOovo Nordisk A/S302
进行中（未招募）
不适用
Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2012-004826-92-NLovo Nordisk A/S798
进行中（未招募）
不适用
Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2012-004827-19-HUovo Nordisk A/S1,200
进行中（未招募）
1 期
Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetesDiabetes Mellitus, Type 2MedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-004827-19-PTovo Nordisk A/S1,200